January 30th, 2017
As posted at http://news.emory.edu/stories/2017/01/del_la_rosa_georgia_bio/index.html
Georgia Bio has honored Abel De La Rosa, PhD, chief scientific officer of Drug Innovation Ventures at Emory (DRIVE) and the Emory Institute for Drug Development (EIDD) with a 2017 Community Award. Each year Georgia Bio recognizes individuals, companies and organizations for significant contributions to Georgia’s life sciences industry with its Georgia Bio Community Awards. The recipients were honored at the 19th Annual Awards Dinner on January 26.
DRIVE and EIDD are focused on the discovery and development of antiviral drugs for the treatment of viral diseases of unmet medical need and global concern.
Prior to joining Emory, De La Rosa was senior vice president of business development and scientific affairs for Pharmasset. From 2002 until its acquisition by Gilead Sciences (Nasdaq: GILD) for $11 billion in 2012, he was responsible for licensing, strategic transactions and alliance management of collaborations and partnerships with pharmaceutical companies and universities.
De La Rosa is being honored for outstanding achievements in the life sciences industry, including his leadership at Pharmasset and current role at DRIVE, along with continued support of Georgia Bio activities.
Learn more about the Georgia Bio Awards at www.gabio.org/awards